Incidence and risk of xerosis with targeted anticancer therapies

Background Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. Objective We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. Methods The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. Results The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P less than .001). Limitations The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. Conclusion Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.

• Fecha de publicación: 2015
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/22471
• Acceso en línea: https://doi.org/10.1016/j.jaad.2014.12.010; https://repository.urosario.edu.co/handle/10336/22471
• Palabra clave: Afatinib; Alemtuzumab; Alitretinoin; Anastrozole; Antineoplastic agent; Axitinib; Bevacizumab; Bexarotene; Bortezomib; Bosutinib; Brentuximab vedotin; Cabozantinib; Carfilzomib; Ceritinib; Cetuximab; Crizotinib; Dabrafenib; Daclizumab; Dasatinib; Denileukin diftitox; Denosumab; Erlotinib; Everolimus; Exemestane; Fulvestrant; Gefitinib; Ibritumomab tiuxetan; Ibrutinib; Trastuzumab emtansine; Unindexed drug; Antineoplastic agent; Antineoplastic hormone agonists and antagonists; Enzyme inhibitor; Hormone antagonist; Monoclonal antibody; Tumor protein; Age distribution; Article; Cancer chemotherapy; Cancer patient; Cancer registry; Controlled clinical trial (topic); Dermatologist; Drug therapy; High risk patient; Human; Incidence; Medical society; Medline; Molecularly targeted therapy; Neoplasm; Phase 1 clinical trial (topic); Phase 2 clinical trial (topic); Phase 3 clinical trial (topic); Priority journal; Randomized controlled trial (topic); Risk factor; Skin manifestation; Systematic review; Web of science; Xerosis; Adverse effects; Antagonists and inhibitors; Chemically induced; Complication; Meta analysis; Molecularly targeted therapy; Neoplasms; Prospective study; Risk; Severity of illness index; Skin diseases; Antineoplastic agents; Enzyme inhibitors; Hormone antagonists; Humans; Incidence; Molecular targeted therapy; Neoplasm proteins; Neoplasms; Prospective studies; Risk; Severity of illness index; Skin diseases; Cd20; Cd52; Dry skin; Egfr; Hdac; Her2; Incidence; Key words bcr-abl; Mek; Mtor; Raf; Risk; Vegfr; Xerosis; phase ii as topic; phase iii as topic; hormonal; monoclonal; Antibodies; Antineoplastic agents; Clinical trials; Clinical trials
• License: Abierto (Texto Completo)